HCA Healthcare, Inc. HCA
Composite 57/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 31/100 — a moderate mark against it.
Quality ranks 74/100 — a moderate point in its favour. Growth ranks 60/100 — a slight point in its favour. Balance-sheet strength ranks 58/100 — a slight point in its favour.
Momentum ranks 31/100 — a moderate mark against it. Income ranks 41/100 — a slight mark against it.
What the company does HCA Healthcare operates 182 hospitals and 2,300+ sites across 20 states, offering acute care, emergency services, outpatient surgery, and diagnostic imaging. Its integrated network spans general hospitals, freestanding emergency centers, urgent care clinics, and physician practices.
Key financials HCA posts ROE 136.3%, ROA 12.3%, and ROCE 29.4%, with gross margins 42.6% and net margins 8.8%. Revenue grew 7.1% and EPS 15.6%, supported by operating margins of 15.2%. Debt/EBITDA is 3.20 and interest coverage 5.25, indicating manageable leverage.
Stock health Sideravia scores Quality 73.5 and Valuation 54.4 but Momentum 37.4 and Income 40.4. Piotroski F-Score is 6/9 and Altman Z 2.58, suggesting moderate financial health. RSI(14) is 64.00, indicating mild upward pressure.
Price vs fair value HCA trades at a discount of 5.90% versus the analyst mean target of 454.57. - Analysts highlight “exciting potential” for HCA while dismissing peers (StockStory 2026-08-18) - Recent articles cite “explosive upside potential” for HCA (StockStory 2026-08-17) - Sector peers like Tenet face scrutiny on growth sustainability (Zacks 2026-08-17) - Broader hospital group sentiment weighed by Universal Health’s 21% YTD drop (Zacks 2026-08-20)
Looking forward Forward P/E 13.85 and EV/EBITDA 8.84 suggest valuation support, but high PEG 32.13 reflects growth expectations. Dividend yield is 0.7% with a conservative payout ratio of 10.1%.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.